Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ORIN 1001

Next Previous
X
Search
Drug Profile

ORIN 1001

Alternative Names: ORIN-1001

Latest Information Update: 17 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fosun Orinove
  • Class Antifibrotics; Antineoplastics; Small molecules
  • Mechanism of Action ERN2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Solid tumours
  • No development reported Idiopathic pulmonary fibrosis

Most Recent Events

  • 31 Dec 2024 Orinove terminates a phase I trial in Idiopathic pulmonary fibrosis in USA due to the ongoing partnership activities(PO) (NCT04643769)
  • 28 Mar 2024 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis in USA (PO, Tablet)
  • 02 Jun 2023 Updated adverse events, efficacy and pharmacokinetic data from a phase I/II trial in Solid tumors presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top